- Home
- BMEA vs LODE Comparison
BMEA vs LODE Comparison
Compare BMEA & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- LODE
- Stock Information
- Founded
- BMEA 2017
- LODE 2008
- Country
- BMEA United States
- LODE United States
- Employees
- BMEA N/A
- LODE N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- LODE Major Chemicals
- Sector
- BMEA Health Care
- LODE Industrials
- Exchange
- BMEA Nasdaq
- LODE Nasdaq
- Market Cap
- BMEA 114.3M
- LODE 119.2M
- IPO Year
- BMEA 2021
- LODE N/A
- Fundamental
- Price
- BMEA $1.93
- LODE $2.91
- Analyst Decision
- BMEA Strong Buy
- LODE Hold
- Analyst Count
- BMEA 10
- LODE 1
- Target Price
- BMEA $15.70
- LODE $4.00
- AVG Volume (30 Days)
- BMEA 559.5K
- LODE 1.0M
- Earning Date
- BMEA 10-28-2025
- LODE 10-21-2025
- Dividend Yield
- BMEA N/A
- LODE N/A
- EPS Growth
- BMEA N/A
- LODE N/A
- EPS
- BMEA N/A
- LODE N/A
- Revenue
- BMEA N/A
- LODE $3,280,749.00
- Revenue This Year
- BMEA N/A
- LODE $16.44
- Revenue Next Year
- BMEA N/A
- LODE $800.34
- P/E Ratio
- BMEA N/A
- LODE N/A
- Revenue Growth
- BMEA N/A
- LODE 58.55
- 52 Week Low
- BMEA $1.29
- LODE $1.67
- 52 Week High
- BMEA $13.07
- LODE $10.10
- Technical
- Relative Strength Index (RSI)
- BMEA 55.47
- LODE 59.52
- Support Level
- BMEA $1.77
- LODE $2.27
- Resistance Level
- BMEA $2.08
- LODE $2.55
- Average True Range (ATR)
- BMEA 0.11
- LODE 0.16
- MACD
- BMEA 0.01
- LODE 0.09
- Stochastic Oscillator
- BMEA 51.61
- LODE 79.01
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.